1. Home
  2. Analysis
  3. Zolmitriptan
  4. Cimzia

Zolmitriptan and Cimzia drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 28 people who take Zolmitriptan and Cimzia. Common interactions include cough among females.

The phase IV clinical study analyzes what interactions people who take Zolmitriptan and Cimzia have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 01, 2023

28 people who take Zolmitriptan and Cimzia together, and have interactions are studied.

What is Zolmitriptan?

Zolmitriptan has active ingredients of zolmitriptan. It is used in migraine. Currently, eHealthMe is studying from 2,275 Zolmitriptan users.

What is Cimzia?

Cimzia has active ingredients of certolizumab pegol. It is used in rheumatoid arthritis. Currently, eHealthMe is studying from 101,925 Cimzia users.

Number of Zolmitriptan and Cimzia reports submitted per year:

Zolmitriptan and Cimzia drug interactions.

Common Zolmitriptan and Cimzia drug interactions by gender *:

female:

  1. Cough
  2. Lower respiratory tract infection
  3. Drug ineffective
  4. Sacroiliitis
  5. Spinal pain
  6. Ventricular tachycardia
  7. Arthralgia
  8. Anxiety
  9. Arthritis
  10. Blister

male:

n/a

Common Zolmitriptan and Cimzia drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Drug ineffective
  2. Musculoskeletal stiffness
  3. Sacroiliitis
  4. Spinal pain

40-49:

n/a

50-59:

  1. Cough
  2. Lower respiratory tract infection
  3. Arthralgia
  4. Arthritis
  5. Joint swelling
  6. Musculoskeletal stiffness
  7. Amnesia
  8. Anxiety
  9. Blister
  10. Burning sensation

60+:

n/a

Common conditions people have *:

  1. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 13 people, 46.43%
  2. Neuropathy Peripheral (surface nerve damage): 2 people, 7.14%
  3. Intervertebral Disc Protrusion (spinal disc protrusion): 2 people, 7.14%
  4. Hypoaesthesia (reduced sense of touch or sensation): 2 people, 7.14%
  5. Hypersensitivity: 2 people, 7.14%
  6. High Blood Pressure: 2 people, 7.14%
  7. Exostosis (formation of new bone on the surface of a bone): 2 people, 7.14%
  8. Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 2 people, 7.14%
  9. Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Zolmitriptan and Cimzia?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Common Zolmitriptan drug interactions:

Browse interactions between Zolmitriptan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Cimzia drug interactions:

Browse interactions between Cimzia and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on zolmitriptan and certolizumab pegol (the active ingredients of Zolmitriptan and Cimzia, respectively), and Zolmitriptan and Cimzia (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Zolmitriptan and Cimzia.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.